Trial Profile
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Acronyms SADAL
- Sponsors Karyopharm Therapeutics
- 22 Mar 2024 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 06 Dec 2022 Planned End Date changed from 1 Dec 2024 to 1 Nov 2027.
- 06 Dec 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Apr 2027.